HGS pays $50mm up front for rights to FivePrime anticancer candidate
Executive Summary
A week after gaining FDA approval for Benlysta (the first lupus medicine to get approved in 50 years), Human Genome Sciences Inc. (HGS) has shelled out $50mm up front for exclusive rights to develop and sell FP1039, an anticancer candidate belonging to FivePrime Therapeutics Inc. (antibodies and protein therapeutics).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice